Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Description of key information

Key value for chemical safety assessment

Skin sensitisation

Endpoint conclusion
Endpoint conclusion:
adverse effect observed (sensitising)
Additional information:

No studies are available for hydroxyethylpiperazine mixture. Studies concerning skin sensitisation are available for the single components of the mixture (piperazine CAS 110-85-0 and 2-piperazin-1-ylethanol CAS 103-76-4).

In a guinea pig maximisation test according to Magnusson-Kligmann (Leung, 1997, CAS 110-85-0 and CAS 103-76-4), groups of 10 male and 10 female guinea pigs received intradermal, of 0,1 mL 5% piperazine or 2-piperazin-1-ylethanol solution and epicutaneous induction of 50% solution of piperazine or 100% of 2-piperazin-1-ylethanol, for 48 h respectively. Epicutaneous challenge was undertaken after 14 days with either 25% of piperazine or 100% of 2-piperazin-1-ylethanol. 5% of the animals treated with piperazine and 10% of the animals treated with 2-piperazin-1-ylethanol showed signs of sensitization. These results lead to the conclusion that piperazine and 2-piperazin-1-ylethanol have a weak sensitising potential.

Skin sensitisation have been noted among humans and worker exposed to piperazine (CAS 110 -85 -0).

Since these effects are known for piperazine and piperazine is a constituent of about 15% in hydroxethylpiperazine mixture it is assumed that hydroxethylpiperazine mixture will also show skin sensitising properties.

Migrated from Short description of key information:
No studies are available for hydroxyethylpiperazine mixture. Studies concerning skin sensitisation are available from two of the three single components of the mixture (piperazine CAS 110-85-0 and 2-piperazin-1-ylethanol CAS 103-76-4).
GPMT: not sensitising (Leung, 1997, CAS 110-85-0 and CAS 103-76-4)
Skin sensitisation in humans: sensitising (EU risk assessment of piperazine (CAS 110-85-0), 2005)

Respiratory sensitisation

Endpoint conclusion
Endpoint conclusion:
adverse effect observed (sensitising)
Additional information:

No studies are available for hydroxyethylpiperazine mixture. Occupational observations concerning respiratory sensitisation in humans are available for one constituent of the mixture (piperazine CAS 110-85-0). Respiratory sensitisations have been noted among workers exposed to piperazine.

Since these effects are known for piperazine and piperazine is a constituent of about 15% in hydroxethylpiperazine mixture it is assumed that hydroxethylpiperazine mixture will also show respiratory sensitisation properties.

Migrated from Short description of key information:
No studies are available for hydroxyethylpiperazine mixture. Occupational observations concerning respiratory sensitisation in humans are available for one constituent of the mixture (piperazine CAS 110-85-0).
Respiratory sensitisation in humans: sensitising (EU risk assessment of piperazine (CAS 110-85-0), 2005)

Justification for classification or non-classification

Dangerous Substance Directive (67/548/EEC)

The available studies are considered reliable and suitable for classification purposes under 67/548/EEC. As a result the substance is considered to be classified for skin (R43) and respiratory sensitisation (R42) under Directive 67/548/EEC, as amended for the 28th time in Directive 2001/59/EC.

 

Classification, Labeling, and Packaging Regulation (EC) No. 1272/2008

The available experimental test data are reliable and suitable for classification purposes under Regulation 1272/2008. As a result the substance is considered to be classified for skin (Cat. 1) and respiratory sensitisation (Cat. 1) under Regulation (EC) No. 1272/2008.